These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 24862180

  • 1. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.
    Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH.
    Int J Cancer; 2015 Jan 15; 136(2):443-51. PubMed ID: 24862180
    [Abstract] [Full Text] [Related]

  • 2. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C, von Römer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, Sauer R, Rödel C, Rödel F.
    Int J Radiat Oncol Biol Phys; 2009 Aug 01; 74(5):1455-60. PubMed ID: 19231102
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of VEGF-C, semaphorin 3F, and neuropilin-2 expression in oral squamous cell carcinomas and their relationship with lymphangiogenesis.
    Zhang B, Gao Z, Sun M, Li H, Fan H, Chen D, Zheng J.
    J Surg Oncol; 2015 Mar 15; 111(4):382-8. PubMed ID: 25475162
    [Abstract] [Full Text] [Related]

  • 4. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA, Keren Paz GE, Chen LY, Herr HW, Dalbagni G.
    BJU Int; 2013 Jul 15; 112(1):54-9. PubMed ID: 23146082
    [Abstract] [Full Text] [Related]

  • 5. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, Dunst J, Sauer R, Rödel C.
    J Clin Oncol; 2006 May 20; 24(15):2318-24. PubMed ID: 16710030
    [Abstract] [Full Text] [Related]

  • 6. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
    Inoue M, Koga F, Yoshida S, Tamura T, Fujii Y, Ito E, Kihara K.
    Int J Radiat Oncol Biol Phys; 2014 Oct 01; 90(2):303-11. PubMed ID: 25304790
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL.
    Eur Urol; 2012 Apr 01; 61(4):705-11. PubMed ID: 22101114
    [Abstract] [Full Text] [Related]

  • 8. Cytoplasmic neuropilin 2 is associated with metastasis and a poor prognosis in early tongue cancer patients.
    Ong HS, Gokavarapu S, Xu Q, Tian Z, Li J, Ji T, Zhang CP.
    Int J Oral Maxillofac Surg; 2017 Oct 01; 46(10):1205-1219. PubMed ID: 28602571
    [Abstract] [Full Text] [Related]

  • 9. Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy.
    Keck B, Ott OJ, Häberle L, Kunath F, Weiss C, Rödel C, Sauer R, Fietkau R, Wullich B, Krause FS.
    World J Urol; 2013 Oct 01; 31(5):1023-8. PubMed ID: 23090757
    [Abstract] [Full Text] [Related]

  • 10. Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer.
    Förster S, Givehchi M, Nitschke K, Mayr T, Kilian K, Dutta S, Datta K, Nuhn P, Popovic Z, Muders MH, Erben P.
    Genes (Basel); 2021 Apr 09; 12(4):. PubMed ID: 33918816
    [Abstract] [Full Text] [Related]

  • 11. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F, Fujii Y, Masuda H, Numao N, Yokoyama M, Ishioka J, Saito K, Kawakami S, Kihara K.
    BJU Int; 2012 Sep 09; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [Abstract] [Full Text] [Related]

  • 12. Concurrent Expression of VEGF-C and Neuropilin-2 Is Correlated with Poor Prognosis in Glioblastoma.
    Zhao H, Hou C, Hou A, Zhu D.
    Tohoku J Exp Med; 2016 Feb 09; 238(2):85-91. PubMed ID: 26753562
    [Abstract] [Full Text] [Related]

  • 13. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
    Zapatero A, Martin de Vidales C, Arellano R, Bocardo G, Pérez M, Ríos P.
    Urol Oncol; 2010 Feb 09; 28(4):368-74. PubMed ID: 19362865
    [Abstract] [Full Text] [Related]

  • 14. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W, Breyer J, Herdegen S, Eder F, Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW, Burger M, Hartmann A.
    Int Urol Nephrol; 2017 Mar 09; 49(3):431-437. PubMed ID: 28035618
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
    Sauer R, Birkenhake S, Kühn R, Wittekind C, Schrott KM, Martus P.
    Int J Radiat Oncol Biol Phys; 1998 Jan 01; 40(1):121-7. PubMed ID: 9422567
    [Abstract] [Full Text] [Related]

  • 16. Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
    Borkowetz A, Froehner M, Rauner M, Conrad S, Erdmann K, Mayr T, Datta K, Hofbauer LC, Baretton GB, Wirth M, Fuessel S, Toma M, Muders MH.
    Int J Cancer; 2020 May 01; 146(9):2619-2627. PubMed ID: 31509606
    [Abstract] [Full Text] [Related]

  • 17. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
    Weiss C, Rödel F, Ott O, Engehausen DG, Papadopoulos T, Sauer R, Rödel C.
    Strahlenther Onkol; 2007 Oct 01; 183(10):552-6. PubMed ID: 17896086
    [Abstract] [Full Text] [Related]

  • 18. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H.
    Eur Urol; 2012 Jul 01; 62(1):118-25. PubMed ID: 22101115
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
    Suzuki K, Morita T, Tokue A.
    Int J Urol; 2005 Feb 01; 12(2):152-8. PubMed ID: 15733109
    [Abstract] [Full Text] [Related]

  • 20. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS, Jeong CW, Kwak C, Kim HH, Moon KC, Ku JH.
    PLoS One; 2017 Feb 01; 12(12):e0189354. PubMed ID: 29244843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.